Alzheimers disease
Conditions
Interventions
RO7126209 (trontinemab) : RO7126209 will be administered once intravenously at designated dose
Sponsors
Nanki Toshihiro
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Written informed consent. 2. Healthy Japanese man who is 20 to 40 years of age at the time of informed consent. 3. Individuals who are judged to be healthy based on their medical, history surgical history, or physical examination. 4. Body mass index (weight [kg]/[height [m]2) of 18.5 to 25.0 kg/m2 at screening. 5. Individuals who have agreed to abstinence or to use contraception methods and to refrain from sperm donation during the study treatment period and for a certain period after administration of the investigational drug.
Exclusion criteria
Exclusion criteria: 1. Individuals with cardiovascular, renal, hepatic, gastrointestinal, immunological, neurological, endocrine, metabolic, cerebrovascular, or bronchopulmonary diseases and individuals with a history of these diseases and disorder kidney, liver, or cardiorespiratory function. 2. Individuals affected by hypersensitivity to biological products or excipients in pharmaceutical products. 3. Subjects who participated in any clinical trial within 4 months before administration of the investigational product and who received the investigational product (including placebo). 4. Individuals who have received or have taken prescription drugs within 1 month before administration of the investigational product.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety Observation | — |
Secondary
| Measure | Time frame |
|---|---|
| safety Measurement | — |
Contacts
Public ContactClinical trials information
Chugai Pharmaceutical Co., Ltd.
Outcome results
None listed